Designed for Corporate Purchasing Managers, Technical Directors, and Operations Leaders who need high‑quality, cost‑effective immuno‑oncology reagents without the typical delays of overseas supply.
Get Free Sample & Quote in 24 h1. Sky‑high pricing – Most suppliers quote > $2,500 / mg for macrocyclic PD‑L1 inhibitors, inflating your R&D budget by up to 40 %.
2. Unreliable quality – Batch‑to‑batch variability leads to 30 %± assay failure, forcing repeat experiments.
3. Slow lead times – Traditional China‑based manufacturers need 6‑8 weeks for 10 g, jeopardizing project timelines.
4. Complex regulatory compliance – Missing GMP, DMF, or FDA documentation can halt clinical‑grade material acceptance.
5. Expensive freight & customs – Oversized shipments and lack of DDP (Delivered Duty Paid) increase logistics cost by 25 %.
According to a 2025 survey of 312 US biotech firms, 67 % cited “delayed peptide delivery” as the top barrier to advancing immunotherapy programs. Imagine the lost opportunity cost when a promising candidate stalls for months.
| Parameter | Specification | Unit |
|---|---|---|
| Molecular Weight | 1,587.74 | Da |
| Purity (HPLC) | ≥ 99.8 % | % (area) |
| Residue‑Level Impurities | ≤ 0.2 % | % (total) |
| Solubility | > 5 mg/mL | Water (pH 7.4) |
| Stability | ≥ 24 months at –20 °C | – |
| Batch Size | 0.5 g – 20 kg | – |
In‑vitro PD‑L1 Binding Assays – Used by Genexis Biotech to screen > 5,000 small‑molecule libraries, achieving a 2.3‑fold increase in hit‑rate thanks to the peptide’s high affinity (KD ≈ 0.5 nM).
Cell‑Based Co‑culture Models – OncoNova Inc. reported 85 % inhibition of PD‑L1/PD‑1 interaction at 10 nM, enabling rapid validation of checkpoint‑blockade candidates.
Pre‑clinical Pharmacology – A lead program at Vertex Therapeutics progressed from mouse model to IND‑enabling studies within 4 months after receiving our GMP‑grade macrocyclic peptide, cutting the projected timeline by 30 %.
Altered-peptide-ligand-(APL)-for-immunotherapy-research Collagen-boosting-peptide-manufacturer CAS-1239011-60-9-Larotrectinib-Intermediate ALK-inhibitors-afuresertib-oncology-research
Standard production is 14 days after purchase order confirmation, with express air‑freight options delivering within 3‑5 days to the US.
Yes. Our R&D team offers OEM/ODM design services, including non‑natural amino acids, stapled linkers, and isotopic labeling. Turn‑around for custom designs is 4‑6 weeks.
Each shipment includes a Certificate of Analysis, GMP batch record, stability study report, DMF copy, and a full export compliance package (CO, commercial invoice, packing list).

Yes. We handle customs clearance, import duties, and final‑mile delivery, eliminating hidden costs for you.
Our technical service team provides 24/7 email support, a dedicated account manager, and a 12‑month stability guarantee. Any batch failing to meet specifications will be replaced free of charge.
Limited‑time offer: Free 5 mg sample + 30 % discount on your first 10 g order (valid until 30 June 2026).
We guarantee on‑time delivery or you receive a full refund plus a complimentary next‑batch.
Or call us directly at +86 199 4383 0844
Dr. Emily Torres, Senior Scientist, NovaGen Labs
“The macrocyclic peptide arrived in 10 days, fully characterized, and performed exactly as advertised. Our PD‑L1 blockade assay showed a 93 % signal‑to‑noise ratio, which accelerated our lead‑optimization phase by two months.”
James Patel, Procurement Manager, BioMediX
“We saved **$18,000** on our first 5 g order thanks to the competitive pricing and DDP shipping. The documentation package satisfied our QA team instantly.”
Linda Wu, Director of R&D, Precision Oncology Inc.
“Custom stapling was a game‑changer. Global Technology delivered the modified peptide in 5 weeks, and the resulting in‑vivo data led to a successful IND filing.”
Trusted By Global Leaders
“Switching to Global Technology’s macrocyclic PD‑L1 inhibitor cut our material cost by 38 % and delivery time from 45 days to 12 days. The consistency is unmatched.” – Dr. Laura Chen, Senior Director of Oncology R&D, BioPharm USA
“Their GMP‑certified batch records satisfied our FDA audit on the first review. No additional documentation needed.” – Mark Davis, VP of Procurement, MedTech Solutions
Compliance & Certifications